Home » Stocks » Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd. (GLMD)

Stock Price: $3.21 USD -0.11 (-3.31%)
Updated Oct 26, 2020 4:00 PM EDT - Market closed
After-hours: $3.37 +0.16 (4.98%) Oct 26, 5:10 PM

Stock Price Chart

Key Info

Market Cap 67.77M
Revenue (ttm) n/a
Net Income (ttm) -20.46M
Shares Out 21.11M
EPS (ttm) -1.16
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 26, 2020
Last Price $3.21
Previous Close $3.32
Change ($) -0.11
Change (%) -3.31%
Day's Open 3.30
Day's Range 3.16 - 3.30
Day's Volume 37,469
52-Week Range 3.02 - 7.38

More Stats

Market Cap 67.77M
Enterprise Value n/a
Earnings Date (est) Nov 9, 2020
Ex-Dividend Date n/a
Shares Outstanding 21.11M
Float 15.65M
EPS (basic) -0.97
EPS (diluted) -1.16
FCF / Share -0.71
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 47,231
Short Ratio 0.54
Short % of Float 0.30%
Beta 2.47
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 1.17
Revenue n/a
Operating Income -22.38M
Net Income -20.46M
Free Cash Flow -14.95M
Net Cash 75.25M
Net Cash / Share 3.56
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -21.60%
ROE -34.53%
ROIC -34.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 4
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$19.60*
(510.59% upside)
Low
10.0
Current: $3.21
High
29.0
Target: 19.60
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue-2.041.090.47----
Revenue Growth-87.83%132.33%-----
Gross Profit-2.041.090.47----
Operating Income-22.38-10.72-12.36-16.88-10.88-9.14-14.57-3.14
Net Income-20.46-9.86-12.30-16.95-10.62-9.10-17.49-3.15
Shares Outstanding21.1118.1412.4911.3711.1010.325.074.96
Earnings Per Share-0.97-0.54-0.98-1.49-0.96-0.88-3.45-0.63
Operating Cash Flow-14.94-9.02-12.07-12.13-8.47-9.24-2.52-3.08
Capital Expenditures-0.01-0.09-0.01--0.16-0.77--0.03
Free Cash Flow-14.95-9.11-12.08-12.13-8.63-10.01-2.52-3.11
Cash & Equivalents75.6090.1919.0015.4523.0031.990.140.72
Total Debt0.35------1.84
Net Cash / Debt75.2590.1919.0015.4523.0031.990.14-1.13
Assets77.1490.6019.6416.4524.2632.930.170.76
Liabilities7.292.713.855.382.721.522.122.74
Book Value69.8587.8915.8011.0821.5531.41-1.95-1.98
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Galmed Pharmaceuticals Ltd.
Country Israel
Employees 17
CEO Allen Baharaff

Stock Information

Ticker Symbol GLMD
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: GLMD
IPO Date March 13, 2014

Description

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is completed ARREST Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. It also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. Galmed Pharmaceuticals Ltd. has a research agreement with Gannex Pharma Company to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of non-alcoholic steatohepatitis. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.